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The summary slide should be changed to:
• Landiolol, an ultra-short-acting b-blocker, is rapidly metabolized to inactive forms in the blood and liver, resulting in a short half-life of approximately 4 min in human blood. In addition, it selectively binds to b1 receptors, with a b1 receptor selectivity (b1/b2) as high as 251.
• The J-Land study was designed as a central registration, prospective, multicenter, singleblind, randomized, parallel-group study to evaluate the efficacy and safety of intravenous landiolol for achieving rapid control of tachycardia in patients with atrial fibrillation (AF)/atrial flutter (AFL) and left ventricular (LV) dysfunction. The primary efficacy endpoint was the percentage of patients with both a heart rate (HR) \110 beats/min (bpm) and C20 % decrease from baseline at 2 h after administration.
• Two hundred patients with AF/AFL, HR C120 bpm, and LV ejection fraction (LVEF) 25-50 % were randomized to receive either landiolol (n = 93) or digoxin (n = 107).
• This subgroup analysis of the J-Land study indicated that landiolol was more useful, regardless of patient characteristics, as compared with digoxin in AF/AFL patients complicated with LV dysfunction. Particularly, in patients with impaired renal function, landiolol should be preferred for the purpose of acute rate control of AF/AFL tachycardia.
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